Supernus Pharmaceuticals, Inc. (SUPN)
43.53
-0.44
(-1.00%)
USD |
NASDAQ |
Sep 04, 16:00
43.54
+0.01
(+0.02%)
Pre-Market: 20:00
Supernus Pharmaceuticals Research and Development Expense (Quarterly) : 29.06M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.06M |
| March 31, 2026 | 38.94M |
| December 31, 2025 | 27.34M |
| September 30, 2025 | 28.87M |
| June 30, 2025 | 21.62M |
| March 31, 2025 | 26.33M |
| December 31, 2024 | 28.05M |
| September 30, 2024 | 28.44M |
| June 30, 2024 | 25.58M |
| March 31, 2024 | 24.32M |
| December 31, 2023 | 22.74M |
| September 30, 2023 | 22.04M |
| June 30, 2023 | 23.78M |
| March 31, 2023 | 20.58M |
| December 31, 2022 | 17.07M |
| September 30, 2022 | 18.42M |
| June 30, 2022 | 15.47M |
| March 31, 2022 | 20.12M |
| December 31, 2021 | 16.78M |
| September 30, 2021 | 16.25M |
| June 30, 2021 | 21.16M |
| March 31, 2021 | 18.68M |
| December 31, 2020 | 15.44M |
| September 30, 2020 | 16.14M |
| June 30, 2020 | 21.65M |
| Date | Value |
|---|---|
| March 31, 2020 | 18.44M |
| December 31, 2019 | 19.79M |
| September 30, 2019 | 16.94M |
| June 30, 2019 | 16.97M |
| March 31, 2019 | 15.39M |
| December 31, 2018 | 29.84M |
| September 30, 2018 | 20.42M |
| June 30, 2018 | 20.04M |
| March 31, 2018 | 18.91M |
| December 31, 2017 | 16.17M |
| September 30, 2017 | 12.98M |
| June 30, 2017 | 10.82M |
| March 31, 2017 | 9.601M |
| December 31, 2016 | 13.25M |
| September 30, 2016 | 7.868M |
| June 30, 2016 | 11.11M |
| March 31, 2016 | 10.56M |
| December 31, 2015 | 9.445M |
| September 30, 2015 | 9.129M |
| June 30, 2015 | 6.878M |
| March 31, 2015 | 3.683M |
| December 31, 2014 | 5.772M |
| September 30, 2014 | 4.657M |
| June 30, 2014 | 4.677M |
| March 31, 2014 | 4.482M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Indivior Pharmaceuticals, Inc. | 7.00M |
| Pfizer Inc. | 2.746B |
| Amphastar Pharmaceuticals, Inc. | 18.30M |
| Collegium Pharmaceutical, Inc. | -- |
| Bristol Myers Squibb Co. | 2.316B |